Get the Stockscreener App
11.54
0.52%
0.06
After Hours:
11.80
0.26
+2.25%
Roivant Sciences Ltd stock is traded at $11.54, with a volume of 5.63M.
It is up +0.52% in the last 24 hours and down -5.64% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$11.48
Open:
$11.41
24h Volume:
5.63M
Relative Volume:
0.92
Market Cap:
$8.53B
Revenue:
$158.30M
Net Income/Loss:
$4.74B
P/E Ratio:
-8.6119
EPS:
-1.34
Net Cash Flow:
$-710.11M
1W Performance:
-3.03%
1M Performance:
-5.64%
6M Performance:
+9.49%
1Y Performance:
-1.20%
1-Day Range:
$11.36
$11.56
1-Week Range:
$11.36
$11.93
52-Week Range:
$8.245
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy? - Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Pacer Advisors Inc. - MarketBeat
Roivant Sciences director sells over $5.8 million in company stock - Investing.com India
Roivant Sciences director Gold sells over $51 million in company stock - Investing.com
QVT Financial LP Adjusts Stake in Roivant Sciences Ltd - GuruFocus.com
Roivant Sciences director sells over $5.8 million in company stock - Investing.com
Director Keith Manchester Sells 503,000 Shares of Roivant Sciences Ltd (ROIV) - GuruFocus.com
QVT Financial LP sells Roivant Sciences shares worth over $10 million By Investing.com - Investing.com South Africa
QVT Financial LP sells Roivant Sciences shares worth over $10 million - Investing.com India
QVT Financial LP sells Roivant Sciences shares worth over $10 million - Investing.com UK
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by DME Capital Management LP - MarketBeat
Freshfields advises Roivant in sale of Dermavant to Organon - Legal Desire News Network
AE Wealth Management LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Roivant Sciences Ltd. (ROIV) the Best Guru Stock To Buy Now? - Insider Monkey
Is Roivant Sciences Ltd. (ROIV) the Best Guru Stock To Buy Now? - Yahoo Finance
Roivant Sciences executive sells shares worth over $2.9 million By Investing.com - Investing.com South Africa
Roivant Sciences CEO sells over $23 million in company stock By Investing.com - Investing.com Canada
Roivant Sciences executive sells shares worth over $2.9 million - Investing.com
Roivant Sciences executive sells shares worth over $2.9 million By Investing.com - Investing.com UK
Roivant Sciences Sees Unusually Large Options Volume (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Farallon Capital Management LLC - MarketBeat
10 Best Guru Stocks To Buy Now - Insider Monkey
Integral Health Asset Management LLC Has $4.23 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Increased by Rubric Capital Management LP - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Roivant Sciences reiterates Buy stock rating on Dermavant subsidiary sale - Investing.com India
Organon to acquire Dermavant in $1.2B deal - NJBIZ
Roivant Sciences maintains buy rating by H.C. Wainwright - Investing.com India
Roivant Sciences stock gets buy rating amid Dermavant deal By Investing.com - Investing.com Australia
Organon to Acquire Roivant’s Dermatology Subsidiary for Up to $1.2B - Femtech Insider
Skin deep: Organon buys Dermavant for $1.2B - BioWorld Online
Freshfields advises Roivant in sale of Dermavant to Organon - Freshfields Bruckhaus Deringer
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B - Benzinga
Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $12.05 - MarketBeat
Roivant Sciences stock gets buy rating amid Dermavant deal - Investing.com India
Roivant dermatology subsidiary to be acquired by Organon - BioPharma Dive
Organon to buy Roivant's dermatology unit for up to $1.2 billion - Reuters
Roivant creates Pulmovant to house lung disorder drug licensed from Bayer - MSN
Organon to Acquire Dermavant - citybiz
Roivant rises as Organon agrees to buy its unit for up to $1.2 billion - XM
Roivant Sciences Subsidiary Acquired for $1.2 Billion - TipRanks
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - Benzinga
Pekin Hardy Strauss Inc. Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Sofinnova Investments Inc. Increases Stake in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences re-elects directors, ratifies EY as auditor - Investing.com India
Roivant Sciences re-elects directors, ratifies EY as auditor - Investing.com
Rhumbline Advisers Trims Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect? - MSN
TD Cowen maintains Hold rating on Roivant Sciences shares, reiterates Buy rating - Investing.com India
Roivant Sciences (NASDAQ:ROIV) Receives Buy Rating from HC Wainwright - MarketBeat
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):